Jean Jacques Bienaime

Director Jean Jacques Bienaime purchases 1,000 shares of KROS at $10.19; stock down 53.8% from 52-week high, part of pre-arranged 10b5-1 plan.

Jean Jacques Bienaime, a director, executed a purchase of 1,000 shares at $10.19 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-05, bringing his holdings to 17,592 shares. This is a scheduled transaction, not a discretionary choice. Bienaime's prior trades at KROS have been mixed: a March 2026 buy showed a 30-day gain of 12.0% followed by a 90-day decline of -8.1%, while subsequent purchases in April and May posted negative 30-day returns of -10.3% and -4.1% respectively. The current stock price of $10.41 is -53.8% from the 52-week high of $22.55, reflecting significant downturn; the company is unprofitable with a net loss of $23,708,000.00 and limited quarterly revenue of $32,000.00. The pre-arranged nature of the purchase negates any inference about timing or conviction.

Director Jean Jacques Bienaime executed 2 sales and 3 buys on same day (10.5K shares each), net neutral in share count.

On 2026-06-05, Jean Jacques Bienaime (Director) filed 2 separate sales totaling 10,500 shares for $203,820.00 alongside 3 separate purchases totaling 10,500 shares for $204,260.00 at prices ranging from $19.27 to $19.48. The transaction left his holdings unchanged at 43,415 shares while the stock currently trades at $18.39, down 33.5% from its 52-week high of $27.65. At IMNM specifically, Bienaime's 5 prior trades show mixed timing outcomes: 3 of 5 prior buys generated positive 90-day returns, while the stock has declined 18.0% over the past 30 days and 14.1% over the past 90 days. The company reported zero revenue in its latest quarter and net income of $-53,839,000.00.

ASND Director Jean Jacques Bienaime bought 500 shares for $111,562.00 across 3 trades at $223.12 blended average on 2026-05-29.

Jean Jacques Bienaime, a Director, executed 3 separate purchases totaling 500 shares for $111,562.00 at a blended average price of $223.12 on 2026-05-29, increasing his holdings from 400 to 900 shares (+125.0%). The purchases occurred when the stock was trading at prices above the current price of $218.06, and the stock has declined -10.5% over the prior 30 days and -3.5% over the prior 90 days. Historically, Bienaime's 10 prior buys across all tickers have averaged +1.3% 30-day returns and -5.2% 90-day returns with a 40.00% win rate, suggesting a mixed track record on buy timing.

Director Jean Jacques Bienaime purchases 400 ASND shares for $95,120.50 total at $237.80 avg; stock down -10.5% in 30 days.

Director Jean Jacques Bienaime made 2 separate purchases totaling 400 shares for $95,120.50 on 2026-05-26, at an average price of $237.80 per share, increasing his holdings from 0 to 400 shares. The current price of $218.06 sits -13.0% below the 52-week high of $250.74, with the stock down -10.5% over the past 30 days. Across his prior open-market activity at all tickers, this director's 10 prior buys posted an average 30-day return of +1.3% but a 90-day return of -5.2% with a 40.00% win rate, indicating a mixed historical pattern that does not clearly predict the outcome of this new accumulation.

Director Bienaime buys 1,000 (1.0K shares) KROS at $10.58 under 10b5-1 plan; stock -56.0% from 52-week high.

Director Jean Jacques Bienaime purchased 1,000 shares of Keros Therapeutics at $10.58 on 2026-05-15 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-05, meaning this was a scheduled transaction rather than a discretionary decision. The stock is currently trading at $9.91, -56.0% from its 52-week high of $22.55 and down 15.1% over the last 30 days. At this same ticker, Bienaime's two prior purchases (2026-04-15 and 2026-03-09) showed mixed results, with 30-day returns of -10.3% and +12.0% respectively. The company is unprofitable with a net loss of $-23,708,000.00 in the latest quarter against revenue of $32,000.00, and trades at a P/E of 4.24 on a market cap of $196,137,104.67. Since the transaction is scheduled under a 10b5-1 plan rather than discretionary, this purchase should be evaluated on plan mechanics and holdings context rather than as a signal of insider conviction.

Director Jean Jacques Bienaime buys 5,000 shares of IMNM at $20.70 on 2026-05-15; stock now -33.5% from 52-week high.

Jean Jacques Bienaime purchased 5,000 shares at $20.70, increasing his holdings by 13.0% to 43.4K shares. The stock has declined -17.2% over 30 days and now trades at $18.38, down -33.5% from its 52-week high of $27.65. The company remains unprofitable, with a most recent quarterly revenue of $0.00 and full-year net income of $-53.8M, reflecting an annual revenue decline of -23.2%. At the same ticker, Bienaime's prior 5 trades show mixed timing: 3 of 5 were well-timed at the 90-day mark, with one prior buy on 2026-03-11 declining -13.6% over 90 days and his most successful trade on 2025-03-25 gaining +12.3%. The current purchase occurs against a backdrop of significant recent weakness and operational challenges.

Director Jean-Jacques Bienaime buys 1,000 KROS shares at $11.70, 37% below 52-week high; stock down 38.1% in 90 days.

Bienaime purchased 1,000 shares at $11.70 on 2026-04-15, increasing his holdings to 8,450 shares from 7,450 shares (+13.4% increase in position). The transaction price sits -46.6% from the 52-week high of $21.84, but the stock has declined -38.1% over the past 90 days, suggesting sustained downward momentum. While his prior buy at KROS on 2026-03-09 showed a strong 30-day return of +12.0%, that outcome was followed by continued weakness in the subsequent 90 days. His cross-ticker buying track record shows 8 prior buys averaging +3.6% over 30 days and +1.1% over 90 days with an 80% win rate. Fundamentally, the company is unprofitable (net income of $-7,280,000.00) with a low P/E of 0.68 and market cap of $230,103,610.11. The recurring purchase activity at depressed levels and the stock's ongoing decline context warrant tracking.

Director Bienaime buys 2,000 shares in 2 transactions for $43,670.00 at IMNM; stock down -22.2% from 52-week high, -15.8% in 30 days.

Director Jean Jacques Bienaime purchased 2 separate tranches totaling 2,000 shares on 2026-03-10 and 2026-03-11 at blended average $21.84, bringing holdings to 38,415 shares. The timing is notable: the stock trades at $20.99 current price, down -15.8% over the past 30 days and -22.2% from its 52-week high of $26.97. His prior 5 trades at IMNM showed 4 of 5 well-timed at the 90-day mark, with prior buys averaging +1.4% to +12.3% over 90 days. However, the company's fundamentals are deteriorating: revenue declined -23.2% year-over-year, with quarterly revenue at $0.00 and net loss of $-57,457,000.00. This insider purchase occurs in a window of significant near-term weakness but against a backdrop of operational challenges that may warrant scrutiny of the buy rationale.

Keros Director Bienaime buys 2.0K shares at $11.21; stock down -48.4% from 52-week high, posting loss-making Q.

Director Jean Jacques Bienaime purchased 2,000 shares at $11.21 on 2026-03-09, increasing his holdings to 7,450 shares (a 36.7% increase from 5,450 shares). The purchase occurs in a challenging backdrop: Keros reported a quarterly net loss of $-7,280,000.00 on revenue of $14,124,000.00, and the stock has fallen -48.4% from its 52-week high of $21.84, trading at $11.27 currently. Across his cross-ticker track record, Bienaime's prior 7 open-market buys averaged a 90-day return of +1.1%, though his buy decisions have achieved an 80.00% 90-day win rate, suggesting selective success in timing acquisitions. The purchase represents a material expansion of his position in a biotech name in a valuation trough, amid active losses, warranting investor scrutiny of the company's cash runway and therapeutic progress."

Director BIENAIME JEAN JACQUES bought 5,000 shares of IMNM at $9.38 on 2025-06-03; stock now $9.26, -43.9% from 52-week high.

Director BIENAIME JEAN JACQUES purchased 5,000 shares at $9.38 on 2025-06-03, increasing his holdings by 15.9% to 36,415 shares. This comes as Immunome trades $9.26, significantly below its 52-week high of $16.51, reflecting a -43.9% decline from peak levels. The company faces material headwinds: annual revenue contracted 35.5% year-over-year, latest quarter revenue stands at $2.9M, and the firm lost $41.6M in the most recent full fiscal year. His prior purchase on 2025-03-25 at this same ticker showed a +9.5% gain within 30 days, and his 2024-08-16 buy yielded +14.5% in 30 days (though -20.1% at 90 days). At the cross-ticker level, his four prior buys averaged +5.1% 30-day returns but -7.4% at 90 days. This purchase into deteriorated fundamentals and a stock trading near the bottom of its annual range warrants scrutiny of whether IMNM represents a genuine opportunity or a continuation of inconsistent timing at the 90-day mark.